Ocrelizumab is noninferior to fingolimod, demonstrating efficacy and safety in children and adolescents with ...

Be ready for the possible transition from RRMS to SPMS by understanding new symptoms, treatment options, and what to discuss ...

Insights from ECTRIMS 2025, including anticipated presentations, key takeaways, and how emerging research on DMTs in RRMS may affect patient care.

Combining the diabetes medication metformin and the antihistamine clemastine increased myelin repair in people with RRMS, ...

New clinical trial data show children with MS may benefit as much from treatment with Ocrevus as Gilenya – and for some outcomes, more.

Compared with other measures of hypertension, the American Heart Association’s stage II hypertension category had the strongest association with disability worsening in patients with multiple ...

The latest announcement is out from Immunic ( (IMUX) ).

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small ...

Having inactive secondary progressive multiple sclerosis can be confusing. Relapses may stop, but symptoms persist. Get ...

Background Multiple sclerosis (MS) is a common autoimmune illness that causes inflammation, demyelination and neurological damage. Symptom relief and immunotherapy are part of the treatment, but ...

Germany is the first European country to launch the product, with further rollouts across Europe to followThe next-generation ...

A combination of metformin, a common diabetes drug, and clemastine, an antihistamine, can help repair myelin—the protective ...